Mirum Pharmaceuticals Inc (MIRM)

$100.87 +1.04 (1.04%)
Market Cap 6.48B
Revenue (ttm) 521.31M
Net Income (ttm) -23.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4.48%
Debt to Equity Ratio 0.00
Volume 518,100
Avg Vol 853,504
Day's Range N/A - N/A
Shares Out 64.93M
Stochastic %K 94%
Beta 0.52
Analysts Strong Sell
Price Target $135.93

Company Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercializat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 667 4085
Address:
989 East Hillsdale Boulevard, Suite 300, Foster City, United States
Doozio
Doozio Aug. 19 at 12:56 AM
3wt bahhhtom of da base $MIRM ? Then repair?
0 · Reply
LMXPERTEN
LMXPERTEN Aug. 18 at 5:22 PM
$MIRM nice BA and Alagille data. Looking forward to OLE readout! 🤩
0 · Reply
dgbio
dgbio Aug. 18 at 4:15 AM
$MIRM Real-world use of maralixibat in biliary atresia: a case series "In this case series, we observed a meaningful pruritus response in all six patients, with three patients experiencing complete resolution. These results suggest that maralixibat may be a useful treatment option for patients with BA who have cholestatic pruritus". https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2026.1858862/full
0 · Reply
dgbio
dgbio Aug. 18 at 3:56 AM
$MIRM Livmarli Improves Xanthomas and Hypercholesterolemia in Children with Alagille Syndrome https://www.ovid.com/journals/jped/abstract/10.1016/j.jpeds.2026.115108~maralixibat-improves-xanthomas-and-hypercholesterolemia-in?redirectionsource=fulltextview
0 · Reply
wizeinvesting
wizeinvesting Aug. 11 at 8:30 AM
$MIRM $GOOGL $META $MELI $UBER Earnings season is revealing an important disconnect: some companies are delivering strong growth, rising revenue, improving cash flow, and higher guidance, yet their stocks are still under pressure. Alphabet, Meta, Mercado Libre, Uber, and Axon show why short-term market reactions can sometimes obscure stronger underlying fundamentals. For a long-term investor, the opportunity is not simply finding stocks that beat expectations—it is identifying businesses that continue getting stronger even when the... https://www.wizeinvesting.com/p/from-small-deposits-to-strong-results-with-mirm
0 · Reply
dgbio
dgbio Aug. 8 at 1:06 AM
$MIRM It took market two days to figure it out.
1 · Reply
LMXPERTEN
LMXPERTEN Aug. 7 at 5:20 PM
$MIRM same as always. Made 9.5/share here so far. Weak hands. Don’t know what they own. Strong 😎 so happy for the longs here! 🥹👏
0 · Reply
notreload_ai
notreload_ai Aug. 6 at 6:58 PM
$MIRM reported robust Q2 2026 net sales of $176.2 million and hiked guidance, yet MIRM stock fell sharply after the FDA asked for an additional Phase 3 study for its PSC drug volixibat. https://notreload.xyz/xy/mirum-drops-after-volixibat-phase-3-delay/
0 · Reply
DrGonzo69
DrGonzo69 Aug. 6 at 6:16 PM
$MIRM impressive recovery.
0 · Reply
LMXPERTEN
LMXPERTEN Aug. 6 at 2:59 PM
$MIRM jiiiiipppiiiiiiieee!!!!! Loaded up biggie today!!!! Already 5 dollars/share up!!!! Thank you weak hands! 😄😄😄😄😄😄
0 · Reply
Latest News on MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 11, 2026, 4:01 PM EDT - 7 days ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum sinks after FDA recommends conducing Phase 3 study

2026-08-06T17:55:42.000Z - 12 days ago

Mirum sinks after FDA recommends conducing Phase 3 study

Mirum Pharmaceuticals price target lowered to $123 from $129 at Baird

2026-08-06T13:25:44.000Z - 12 days ago

Mirum Pharmaceuticals price target lowered to $123 from $129 at Baird

Mirum Pharmaceuticals price target lowered to $140 from $145 at TD Cowen

2026-08-06T12:48:32.000Z - 13 days ago

Mirum Pharmaceuticals price target lowered to $140 from $145 at TD Cowen

Mirum Pharmaceuticals price target lowered to $137 from $150 at Morgan Stanley

2026-08-06T11:31:06.000Z - 13 days ago

Mirum Pharmaceuticals price target lowered to $137 from $150 at Morgan Stanley

Mirum Pharmaceuticals price target lowered to $135 from $148 at RBC Capital

2026-08-06T11:12:59.000Z - 13 days ago

Mirum Pharmaceuticals price target lowered to $135 from $148 at RBC Capital

Mirum Pharmaceuticals price target lowered to $140 from $185 at H.C. Wainwright

2026-08-06T10:10:47.000Z - 13 days ago

Mirum Pharmaceuticals price target lowered to $140 from $185 at H.C. Wainwright

Mirum Pharmaceuticals price target lowered to $137 from $146 at Citizens

2026-08-06T09:50:43.000Z - 13 days ago

Mirum Pharmaceuticals price target lowered to $137 from $146 at Citizens

Mirum Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Mirum Pharmaceuticals Earnings Call Transcript: Q2 2026

Mirum Pharmaceuticals Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Mirum Pharmaceuticals Earnings release: Q2 2026

Mirum Pharmaceuticals Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

Mirum Pharmaceuticals Quarterly report: Q2 2026

Mirum Pharmaceuticals reports Q2 EPS ($1.06), consensus (75c)

2026-08-05T20:15:53.000Z - 13 days ago

Mirum Pharmaceuticals reports Q2 EPS ($1.06), consensus (75c)

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 5, 2026, 4:01 PM EDT - 13 days ago

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate presentation

Aug 1, 2026, 8:00 AM EDT - 18 days ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Jul 29, 2026, 4:01 PM EDT - 20 days ago

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Mirum treatment of primary sclerosing cholangitis granted FDA orphan status

2026-07-21T18:00:12.000Z - 4 weeks ago

Mirum treatment of primary sclerosing cholangitis granted FDA orphan status

Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board

2026-07-16T13:15:36.000Z - 4 weeks ago

Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board

ARQT

Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital

2026-07-07T11:35:34.000Z - 6 weeks ago

Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital

Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan

2026-07-02T13:45:44.000Z - 6 weeks ago

Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan

Mirum Pharmaceuticals Slides: Corporate presentation

Jul 1, 2026, 7:00 AM EDT - 7 weeks ago

Mirum Pharmaceuticals Slides: Corporate presentation

Biotech ETF Index Surges 10% After Rebalance

Jun 25, 2026, 11:31 AM EDT - 7 weeks ago

Biotech ETF Index Surges 10% After Rebalance

ALKS APGE DFTX DYN KLRA KYMR MANE

Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens

2026-06-15T09:55:32.000Z - 2 months ago

Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens

Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

2026-06-14T21:20:07.000Z - 2 months ago

Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

INCY

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

Jun 14, 2026, 4:35 PM EDT - 2 months ago

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

INCY

Mirum Pharmaceuticals Slides: Study update presentation

Jun 13, 2026, 7:00 AM EDT - 2 months ago

Mirum Pharmaceuticals Slides: Study update presentation

Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley

2026-06-11T11:25:59.000Z - 2 months ago

Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley

VIR

Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026

2026-06-04T12:21:26.000Z - 2 months ago

Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026

INCY

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Jun 4, 2026, 8:05 AM EDT - 2 months ago

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Mirum Pharmaceuticals initiated with a Buy at Citi

2026-06-02T10:20:40.000Z - 2 months ago

Mirum Pharmaceuticals initiated with a Buy at Citi

Mirum announces new data from its rare liver disease programs at EASL

2026-05-31T13:40:06.000Z - 2 months ago

Mirum announces new data from its rare liver disease programs at EASL

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

May 30, 2026, 12:00 PM EDT - 2 months ago

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

May 21, 2026, 8:05 AM EDT - 3 months ago

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

Mirum Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 1:35 PM EDT - 3 months ago

Mirum Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

Mirum Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 3:30 PM EDT - 3 months ago

Mirum Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Mirum Pharmaceuticals initiated with an Outperform at Wolfe Research

2026-05-19T10:10:11.000Z - 3 months ago

Mirum Pharmaceuticals initiated with an Outperform at Wolfe Research

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

May 12, 2026, 11:56 PM EDT - 3 months ago

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

May 12, 2026, 4:01 PM EDT - 3 months ago

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026, 8:00 AM EDT - 3 months ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Mirum Pharmaceuticals Earnings Call Transcript: Q1 2026

Mirum Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Mirum Pharmaceuticals Earnings release: Q1 2026

Mirum Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Mirum Pharmaceuticals Quarterly report: Q1 2026

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:01 PM EDT - 3 months ago

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 3 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum's rare liver disease drug meets main goal in mid-stage study

May 4, 2026, 2:04 PM EDT - 3 months ago

Mirum's rare liver disease drug meets main goal in mid-stage study

Mirum Pharmaceuticals Transcript: Study result

May 4, 2026, 8:30 AM EDT - 3 months ago

Mirum Pharmaceuticals Transcript: Study result

Mirum Pharmaceuticals Slides: Study result

May 4, 2026, 8:30 AM EDT - 3 months ago

Mirum Pharmaceuticals Slides: Study result

Mirum Pharmaceuticals Press release: Study result

May 4, 2026, 8:30 AM EDT - 3 months ago

Mirum Pharmaceuticals Press release: Study result

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

May 4, 2026, 8:00 AM EDT - 3 months ago

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

May 3, 2026, 5:00 PM EDT - 3 months ago

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Apr 29, 2026, 4:01 PM EDT - 3 months ago

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Mirum Pharmaceuticals Slides: Corporate presentation

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Mirum Pharmaceuticals Proxy statement: Proxy filing

Mirum Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Mirum Pharmaceuticals Proxy statement: Proxy filing

Egetis Appoints Tiago Nunes as Chief Medical Officer

Apr 9, 2026, 1:15 AM EDT - 4 months ago

Egetis Appoints Tiago Nunes as Chief Medical Officer

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 10:00 AM EDT - 5 months ago

Mirum Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mirum Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 10:10 AM EDT - 5 months ago

Mirum Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mirum Pharmaceuticals Slides: Corporate presentation

Mar 6, 2026, 6:00 AM EST - 5 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

Mar 5, 2026, 8:00 AM EST - 5 months ago

Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

Mirum Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:10 PM EST - 6 months ago

Mirum Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mirum Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Mirum Pharmaceuticals Earnings Call Transcript: Q4 2025

Mirum Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Mirum Pharmaceuticals Annual report: Q4 2025

Mirum Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Mirum Pharmaceuticals Earnings release: Q4 2025

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

Feb 25, 2026, 4:01 PM EST - 6 months ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate presentation

Feb 25, 2026, 7:00 AM EST - 6 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

Feb 18, 2026, 4:01 PM EST - 6 months ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

Feb 5, 2026, 8:51 AM EST - 6 months ago

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

Feb 5, 2026, 8:00 AM EST - 6 months ago

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Jan 26, 2026, 8:00 AM EST - 7 months ago

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Mirum Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 7 months ago

Mirum Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

Jan 12, 2026, 8:30 AM EST - 7 months ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

Mirum Pharmaceuticals Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 7 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

Jan 9, 2026, 11:55 AM EST - 7 months ago

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:01 PM EST - 7 months ago

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

Dec 19, 2025, 8:30 AM EST - 8 months ago

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

Mirum Pharmaceuticals Transcript: M&A Announcement

Dec 8, 2025, 8:30 AM EST - 9 months ago

Mirum Pharmaceuticals Transcript: M&A Announcement

Mirum Pharmaceuticals Press release: M&A Announcement

Dec 8, 2025, 8:30 AM EST - 9 months ago

Mirum Pharmaceuticals Press release: M&A Announcement

Mirum Pharmaceuticals Slides: M&A Announcement

Dec 8, 2025, 8:30 AM EST - 9 months ago

Mirum Pharmaceuticals Slides: M&A Announcement

Mirum Pharma to buy Bluejay Therapeutics for up to $820 million

Dec 8, 2025, 8:05 AM EST - 9 months ago

Mirum Pharma to buy Bluejay Therapeutics for up to $820 million

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Dec 8, 2025, 8:00 AM EST - 9 months ago

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Mirum Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 2:10 PM EST - 9 months ago

Mirum Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Dec 1, 2025, 8:10 AM EST - 9 months ago

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Mirum Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:40 AM EST - 10 months ago

Mirum Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®

Nov 7, 2025, 8:10 AM EST - 10 months ago

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®

Mirum Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Mirum Pharmaceuticals Earnings Call Transcript: Q3 2025

Mirum Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Mirum Pharmaceuticals Quarterly report: Q3 2025

Mirum Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Mirum Pharmaceuticals Earnings release: Q3 2025

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:01 PM EST - 10 months ago

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate presentation

Nov 4, 2025, 4:00 PM EST - 10 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals Slides: Corporate Presentation

Nov 3, 2025, 6:00 PM EST - 10 months ago

Mirum Pharmaceuticals Slides: Corporate Presentation

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Oct 28, 2025, 4:02 PM EDT - 10 months ago

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Mirum Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 10:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Mirum Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

Mirum Pharmaceuticals Slides: Corporate presentation

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 3:20 PM EDT - 1 year ago

Mirum Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Mirum Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals Earnings Call Transcript: Q2 2025

Mirum Pharmaceuticals Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals Quarterly report: Q2 2025

Mirum Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals Earnings release: Q2 2025

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:01 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate Presentation

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Mirum Pharmaceuticals Slides: Corporate Presentation

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Jul 30, 2025, 4:01 PM EDT - 1 year ago

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Mirum Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 9:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 19, 2025, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

May 9, 2025, 8:30 AM EDT - 1 year ago

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

Mirum Pharmaceuticals Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals Earnings Call Transcript: Q1 2025

Mirum Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals Quarterly report: Q1 2025

Mirum Pharmaceuticals Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals Earnings release: Q1 2025

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:01 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Slides: Corporate Presentation

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 30, 2025, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Apr 14, 2025, 8:30 AM EDT - 1 year ago

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Mirum Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Proxy statement: Proxy Filing

Mirum Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Proxy statement: Proxy Filing

Mirum Pharmaceuticals Slides: Corporate presentation

Apr 14, 2025, 7:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Slides: Corporate presentation

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mar 27, 2025, 8:30 AM EDT - 1 year ago

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mirum Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 10:40 AM EDT - 1 year ago

Mirum Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Mirum Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals Earnings Call Transcript: Q4 2024

Mirum Pharmaceuticals Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals Annual report: Q4 2024

Mirum Pharmaceuticals Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals Earnings release: Q4 2024

Mirum Pharmaceuticals Slides: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals Slides: Q4 2024

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:01 PM EST - 1 year ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Feb 24, 2025, 8:30 AM EST - 1 year ago

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

US FDA approves Mirum Pharma's genetic disorder drug

Feb 21, 2025, 12:01 PM EST - 1 year ago

US FDA approves Mirum Pharma's genetic disorder drug

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Feb 19, 2025, 4:04 PM EST - 1 year ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Mirum Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 12:45 PM EST - 1 year ago

Mirum Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Jan 13, 2025, 8:30 AM EST - 1 year ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Doozio
Doozio Aug. 19 at 12:56 AM
3wt bahhhtom of da base $MIRM ? Then repair?
0 · Reply
LMXPERTEN
LMXPERTEN Aug. 18 at 5:22 PM
$MIRM nice BA and Alagille data. Looking forward to OLE readout! 🤩
0 · Reply
dgbio
dgbio Aug. 18 at 4:15 AM
$MIRM Real-world use of maralixibat in biliary atresia: a case series "In this case series, we observed a meaningful pruritus response in all six patients, with three patients experiencing complete resolution. These results suggest that maralixibat may be a useful treatment option for patients with BA who have cholestatic pruritus". https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2026.1858862/full
0 · Reply
dgbio
dgbio Aug. 18 at 3:56 AM
$MIRM Livmarli Improves Xanthomas and Hypercholesterolemia in Children with Alagille Syndrome https://www.ovid.com/journals/jped/abstract/10.1016/j.jpeds.2026.115108~maralixibat-improves-xanthomas-and-hypercholesterolemia-in?redirectionsource=fulltextview
0 · Reply
wizeinvesting
wizeinvesting Aug. 11 at 8:30 AM
$MIRM $GOOGL $META $MELI $UBER Earnings season is revealing an important disconnect: some companies are delivering strong growth, rising revenue, improving cash flow, and higher guidance, yet their stocks are still under pressure. Alphabet, Meta, Mercado Libre, Uber, and Axon show why short-term market reactions can sometimes obscure stronger underlying fundamentals. For a long-term investor, the opportunity is not simply finding stocks that beat expectations—it is identifying businesses that continue getting stronger even when the... https://www.wizeinvesting.com/p/from-small-deposits-to-strong-results-with-mirm
0 · Reply
dgbio
dgbio Aug. 8 at 1:06 AM
$MIRM It took market two days to figure it out.
1 · Reply
LMXPERTEN
LMXPERTEN Aug. 7 at 5:20 PM
$MIRM same as always. Made 9.5/share here so far. Weak hands. Don’t know what they own. Strong 😎 so happy for the longs here! 🥹👏
0 · Reply
notreload_ai
notreload_ai Aug. 6 at 6:58 PM
$MIRM reported robust Q2 2026 net sales of $176.2 million and hiked guidance, yet MIRM stock fell sharply after the FDA asked for an additional Phase 3 study for its PSC drug volixibat. https://notreload.xyz/xy/mirum-drops-after-volixibat-phase-3-delay/
0 · Reply
DrGonzo69
DrGonzo69 Aug. 6 at 6:16 PM
$MIRM impressive recovery.
0 · Reply
LMXPERTEN
LMXPERTEN Aug. 6 at 2:59 PM
$MIRM jiiiiipppiiiiiiieee!!!!! Loaded up biggie today!!!! Already 5 dollars/share up!!!! Thank you weak hands! 😄😄😄😄😄😄
0 · Reply
UmbraUltra
UmbraUltra Aug. 6 at 2:50 PM
$MIRM got hit on PSC readout risk. The market priced in a possible phase 3. I added on the drop. Can always build lower if the data gets uglier. Biotech is about sizing for the binary event, not timing the bottom.
1 · Reply
StocktwitsNews
StocktwitsNews Aug. 6 at 1:46 PM
Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15% $MIRM $XBI https://stocktwits.com/news/equity/markets/citizens-mirum-unexpected-fda-request-clouds-near-term-outlook-200dma-cracked/cZoJzFZRJ7u
0 · Reply
Ohzipit
Ohzipit Aug. 6 at 1:28 PM
$MIRM
0 · Reply
CH_Expat
CH_Expat Aug. 6 at 12:36 PM
$MIRM @DLAT94 Geht bei mir nicht. Trauma.
1 · Reply
Home_Skillet
Home_Skillet Aug. 6 at 11:28 AM
$MIRM overreaction! Great entry point!
0 · Reply
StocksRGreat1
StocksRGreat1 Aug. 6 at 8:17 AM
$MIRM Cowen lowered Target Price to $140 from $145.
0 · Reply
LMXPERTEN
LMXPERTEN Aug. 6 at 12:24 AM
$MIRM insane reaction! Tomorrow? BIG BUY 😄 (VISTAS was designed pivotal. Though there are amateurs at FDA this should be negotiable. Of course sad with unnecessary delay in submission but no biggie)
1 · Reply
dgbio
dgbio Aug. 5 at 10:50 PM
$MIRM Let's talk numbers. Volixi is about 25% of the total valuation, delay may cut its valuation by about 30%. Delay is not certain, let's say its probability is 50%. The impact on the total valuation is about 4%. At the same time they raise guidance by 2% (midpoint) vs consensus. The overall impact looks negligible.
0 · Reply
OffHisGame88
OffHisGame88 Aug. 5 at 10:37 PM
$MIRM may start a pos at this level
0 · Reply
Polip
Polip Aug. 5 at 9:49 PM
$MIRM they don’t make enough money. They need to dilute
1 · Reply
buddyopalosam
buddyopalosam Aug. 5 at 9:38 PM
$MIRM now ph3 and if they have to raise cash. Thisnis 18 months and this is going to get cut in half
0 · Reply
Jack0007
Jack0007 Aug. 5 at 9:34 PM
$MIRM The earnings call was much more constructive than the headlines. Revenue beat expectations, guidance was raised, management still expects an H1 2027 NDA submission, and the application is essentially ready. They are working through additional FDA discussions and adding more safety data.
0 · Reply